About: Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.78 (+4.71%)
CDIO NASDAQ Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings Inc share price
Atividade de preço de CDIO
Último preço
$ 1,780
Variação (24h)
0,08 USD (4,71%)
Volume
1.95K
Volume (média 4 sem.)
-
Abertura
$ 1,73
Variação do dia
$ 1,73 - $ 1,78
Fechamento anterior
$ 1,70
Último negócio
29 Oct, 2:48 pm GMT+0
Atrasado
29 Oct, 2:48 pm GMT+0
CDIO price performance
Atrasado
29 Oct, 2:48 pm GMT+0
quote.marketSignals